Remove Bioassay Remove In-Vitro Remove In-Vivo Remove RNA
article thumbnail

Accelerating NDA filing through faster carcinogenicity assessment

Drug Discovery World

Until recently, drug carcinogenicity assessment required two different in vivo studies, one of which was typically a two-year lifetime study in rats. Dr Megan MacBride and Dr Caroline Horizny Mitchell , Taconic, examine recent changes to animal testing in drug design. billion and take over 10 years.